New therapies in development for autoimmune diseases: their rationale for combination treatment.
Strand
V
V
Division of Immunology, Stanford University School of Medicine, 306 Ramona Road, Portola Valley, CA 94028, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D019138:Antibodies, Blocking / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D001402:B-Lymphocytes / Q000276:immunology; D003131:Combined Modality Therapy; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000276:immunology; D004359:Drug Therapy, Combination; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000628:therapy; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D019138:Antibodies, Blocking; D016207:Cytokines; D000949:Histocompatibility Antigens Class II; D011948:Receptors, Antigen, T-Cell